We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ultragenyx Receives Priority Review for rhGUS from FDA
Read MoreHide Full Article
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) recently announced that it has submitted regulatory applications in both the U.S. and the EU for recombinant human beta-glucuronidase (rhGUS). This is an investigational candidate that is being developed for the treatment of mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome.
Ultragenyx submitted a biologics license application (BLA) to the FDA and a marketing authorization application (MAA) to the EU. The FDA has accepted the company's BLA on a priority review basis and set a PDUFA action date of Nov 16, 2017. Moreover, the company’s MAA was accepted by the EU and an opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected in the first half of 2018.
Note that rhGUS was previously granted orphan drug designation by the FDA.
Shares of Ultragenyx have underperformed the Zacks classified Medical-Biomed/Genetics industry in the past one year. The stock has lost 16.1% during the period, while the broader industry witnessed a decrease of 11%.
Coming back to the latest news, the regulatory filings were supported by data from a phase III study designed to evaluate the safety and efficacy of rhGUS in patients (n=12) aged 5–35 years for MPS 7 – a rare lysosomal storage disease. In Jul 2016, the company announced positive top-line data from the study. Data demonstrated a rapid and sustained reduction of 64.8% from baseline in urinary GAG (dermatan sulfate) excretion after 24 weeks of treatment, thereby meeting the primary endpoint. It also provided evidence of clinical improvement. Treatment-emergent adverse events were generally mild to moderate in severity.
We note that MPS 7 represents an underserved market with no approved therapies presently available to treat the disease. Approval and successful commercialization of rhGUS will thus be a major boost for the company.
Drugs currently approved for the treatment of other MPS disorders include BioMarin Pharmaceutical Inc.’s (BMRN - Free Report) Aldurazyme, Naglazyme and Vimizim and Shire plc’s Elaprase.
Ultragenyx currently carries a Zacks Rank #3 (Hold). A better-ranked stock in healthcare sector is VIVUS, Inc. , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’s loss per share estimates narrowed from 50 cents to 39 cents for 2017, over the last 30 days. The company posted positive earnings surprises in all four trailing quarters with an average beat of 233.69%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Ultragenyx Receives Priority Review for rhGUS from FDA
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) recently announced that it has submitted regulatory applications in both the U.S. and the EU for recombinant human beta-glucuronidase (rhGUS). This is an investigational candidate that is being developed for the treatment of mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome.
Ultragenyx submitted a biologics license application (BLA) to the FDA and a marketing authorization application (MAA) to the EU. The FDA has accepted the company's BLA on a priority review basis and set a PDUFA action date of Nov 16, 2017. Moreover, the company’s MAA was accepted by the EU and an opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected in the first half of 2018.
Note that rhGUS was previously granted orphan drug designation by the FDA.
Shares of Ultragenyx have underperformed the Zacks classified Medical-Biomed/Genetics industry in the past one year. The stock has lost 16.1% during the period, while the broader industry witnessed a decrease of 11%.
Coming back to the latest news, the regulatory filings were supported by data from a phase III study designed to evaluate the safety and efficacy of rhGUS in patients (n=12) aged 5–35 years for MPS 7 – a rare lysosomal storage disease. In Jul 2016, the company announced positive top-line data from the study. Data demonstrated a rapid and sustained reduction of 64.8% from baseline in urinary GAG (dermatan sulfate) excretion after 24 weeks of treatment, thereby meeting the primary endpoint. It also provided evidence of clinical improvement. Treatment-emergent adverse events were generally mild to moderate in severity.
We note that MPS 7 represents an underserved market with no approved therapies presently available to treat the disease. Approval and successful commercialization of rhGUS will thus be a major boost for the company.
Drugs currently approved for the treatment of other MPS disorders include BioMarin Pharmaceutical Inc.’s (BMRN - Free Report) Aldurazyme, Naglazyme and Vimizim and Shire plc’s Elaprase.
Ultragenyx Pharmaceutical Inc. Price
Ultragenyx Pharmaceutical Inc. Price | Ultragenyx Pharmaceutical Inc. Quote
Zacks Rank and Key Picks
Ultragenyx currently carries a Zacks Rank #3 (Hold). A better-ranked stock in healthcare sector is VIVUS, Inc. , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’s loss per share estimates narrowed from 50 cents to 39 cents for 2017, over the last 30 days. The company posted positive earnings surprises in all four trailing quarters with an average beat of 233.69%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>